ASH 2022 Conference Coverage
Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With PV: Final Results of Low-PV Randomized Phase II Trial
By
ASH 2022 Conference Coverage
FEATURING
Tiziano Barbui
By
ASH 2022 Conference Coverage
FEATURING
Tiziano Barbui
Login to view comments.
Click here to Login
